Lilie Lin, MD
University of Pennsylvania School of Medicine
Pilot study of a novel PARP inhibitor PET tracer in patients with ovarian carcinoma
Targeted agents such as poly-ADP ribose polymerase (PARP) inhibitors are actively being tested alone or in combination with chemotherapy or radiotherapy as promising treatments for ovarian cancer. However, not all patients will respond to and benefit from these therapies. Dr. Lin’s project is to test whether a new imaging technique using a Positron Emission Tomography (PET) tracer for PARP inhibitors can light up areas of known ovarian cancer as well as inform on PARP1 protein activity in tumor biopsies of patients. Developing a non-invasive method to image ovarian cancer patients with tumors exhibiting high PARP1 protein activity would allow better selection of patients for PARP inhibitor therapy by matching the right therapy to the right patient.